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Abstract
Metformin is a widely prescribed drug for the treatment of type 2 diabetes. Previous studies have demonstrated in vitro that
metformin specifically inhibits Complex I of the mitochondrial respiratory chain. This seems contraindicative since muscle
mitochondrial dysfunction has been linked to the pathogenesis of type 2 diabetes. However, its significance for in vivo
skeletal muscle mitochondrial function has yet to be elucidated. The aim of this study was to assess the effects of metformin
on in vivo and ex vivo skeletal muscle mitochondrial function in a rat model of diabetes. Healthy (fa/+) and diabetic (fa/fa)
Zucker diabetic fatty rats were treated by oral gavage with metformin dissolved in water (30, 100 or 300 mg/kg
bodyweight/day) or water as a control for 2 weeks. After 2 weeks of treatment, muscle oxidative capacity was assessed in
vivo using 31P magnetic resonance spectroscopy and ex vivo by measuring oxygen consumption in isolated mitochondria
using high-resolution respirometry. Two weeks of treatment with metformin impaired in vivo muscle oxidative capacity in a
dose-dependent manner, both in healthy and diabetic rats. Whereas a dosage of 30 mg/kg/day had no significant effect, in
vivo oxidative capacity was 21% and 48% lower after metformin treatment at 100 and 300 mg/kg/day, respectively,
independent of genotype. High-resolution respirometry measurements demonstrated a similar dose-dependent effect of
metformin on ex vivo mitochondrial function. In conclusion, metformin compromises in vivo and ex vivo muscle oxidative
capacity in Zucker diabetic fatty rats in a dose-dependent manner.
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Introduction
Metformin is the most commonly prescribed drug to treat type 2
diabetes and it has been in clinical use for decades. Metformin is a
biguanide that lowers blood glucose levels primarily by improving
insulin sensitivity in the liver, where it effectively inhibits
gluconeogenesis [1], whereas it does not have marked hypoglyce-
mic effects [2]. Moreover, metformin enhances insulin sensitivity
in skeletal muscle, thereby stimulating peripheral glucose utiliza-
tion [3].
A number of in vitro studies reported that metformin inhibits
Complex I of the mitochondrial respiratory chain [3–9], thus
limiting the respiratory capacity of the cell and possibly restricting
ATP synthesis. The mechanism through which metformin acts on
Complex I, however, is still not known. Some studies suggest that
metformin binds directly to the mitochondrial membrane phos-
pholipids, thereby altering physicochemical membrane properties
[3,10]. Others contradict this direct mechanism and postulate that
an intact cell is required for metformin’s inhibitory action on
Complex I, involving an indirect pathway via the cell membrane
[6,8].
Treatment of patients with type 2 diabetes with a Complex I
inhibitor seems contraindicative, since muscle mitochondrial
dysfunction has been linked to the pathogenesis of this disease
[11,12]. Moreover, considering that regular exercise is recom-
mended in most guidelines for the treatment of type 2 diabetes
[13,14], it seems even more unfavorable to treat diabetes patients
with a Complex I inhibitor, as it would attenuate their exercise
capacity and consequently their ability to increase insulin
sensitivity via exercise training. The latter has indeed been
demonstrated by Sharoff et al. [15], who observed that the
therapeutic effects of exercise training were absent in patients who
were treated with metformin in conjunction with exercise therapy.
Although the specific inhibitory action of metformin on
Complex I has been shown using in vitro measurements, its
significance for in vivo skeletal muscle mitochondrial function has
yet to be elucidated. The aim of this study was to determine the
effect of metformin on in vivo skeletal muscle oxidative capacity in a
rat model of diabetes using phosphorous (31P) magnetic resonance
spectroscopy (MRS). Lean, healthy and obese, diabetic Zucker
diabetic fatty (ZDF) rats were dosed orally for 2 weeks with
metformin dissolved in water (30, 100 or 300 mg/kg body weight/
day) or water as a control. A dosage of 30 mg/kg/day is typically
prescribed for diabetes patients, while, because of the lower
bioavailability of metformin in rats compared with humans,
,100–300 mg/kg/day metformin is needed to attain similar
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e100525
effects on glucose homeostasis in rats [3,16–21]. 31P MRS
measurements were complemented by ex vivo high resolution
respirometry (HRR) measurements in isolated mitochondria to
interpret the effects of metformin on in vivo oxidative capacity. We
demonstrated that 2 weeks of treatment with metformin compro-
mised in vivo and ex vivo muscle oxidative capacity in ZDF rats in a
dose-dependent manner.
Research Design and Methods
Ethics statement
All experimental procedures were reviewed and approved by
the Animal Experimental Committee of Maastricht University
(permit number: 2011-047). Surgery, MRS experiments and
termination were performed under isoflurane (IsoFlo) anesthesia
with additional pain relief using buprenorphine (Temgesic), and all
efforts were made to minimize suffering.
Animals
Lean, non-diabetic fa/+ and obese, diabetic, fa/fa adult male
ZDF rats (12 weeks of age) were purchased from Charles River
Laboratories (Sulzfield, Germany). The animals were housed
pairwise, in a controlled environment (20uC and 50% relative
humidity on a 12-h light-dark cycle) and given ad libitum access to
water and specific standardized chow for ZDF rats (Purina
Formula 5008, Bioservices, the Netherlands). For 15 days, animals
were dosed with metformin (0, 30, 100 or 300 mg/kg body
weight/day, n = 6 per group) in 1 ml of water directly into the
stomach by oral gavage. Dosing was performed once daily
between 4 and 6 pm. At day 15, in vivo MRS experiments were
performed on the animals between 8 am and 4 pm, i.e. 14–24
hours after the dosage of metformin on the previous day.
Following the MRS measurements, animals were administered
with the last dose of metformin (between 4 and 6 pm). The
following day between 8 and 10 am, i.e. 14–18 hours after the last
dosage of metformin, animals were sacrificed under anesthesia by
incision of the vena cava. The terminal half-life of metformin after
oral administration in rats has been determined to be ,3, 6 and 7
hours at doses of 50, 100 and 200 mg/kg, respectively [22], which
implies that all in vivo and ex vivo experiments were performed
under conditions in which plasma levels of metformin were less
than 5% of the maximum plasma concentrations. One tibialis
anterior (TA) muscle was used for isolation of mitochondria. The
other TA was frozen in liquid nitrogen and stored at 280uC.
Plasma parameters
After 2 weeks of treatment, a blood sample was taken between
12 and 2 pm (i.e. at least 18 hours after the previous dosage of
metformin), after a 4-hour fast, for determination of post-therapy
plasma glucose and insulin concentrations. Plasma glucose
concentrations were determined using an automatic glucometer
(Freestyle, Abbott, IL, USA). Plasma insulin concentrations were
determined with an ultrasensitive rat insulin ELISA kit (Mercodia,
Uppsala, Sweden).
MRS measurements
31P MRS measurements were performed using a horizontal 6.3-
T MR scanner (Bruker, Ettlingen, Germany) with an ellipsoid (10/
18 mm) 31P surface coil. The animals were anaesthetized using
isoflurane (2–3%) combined with medical air (0.6 L/min). 31P
MRS was applied to assess in vivo oxidative capacity of the TA
muscle, as described previously [23]. A fully relaxed spectrum
(repetition time = 20 s, 32 averages) was recorded first, followed
by a time series of spectra (repetition time = 5 s, 4 averages)
obtained during a resting period of 3 min, 2 min of electrical
stimulation and 15 min of recovery. Electrodes were implanted
subcutaneously along the distal nerve trajectory of the N. peroneus
communis to electrically stimulate the TA muscle. Pulses with a
stimulation voltage of approximately 3 V were used to reach
similar levels of phosphocreatine (PCr) depletion for the different
animals.
MRS data analysis
MR spectra were fitted in the time domain using a nonlinear
least squares algorithm (advanced method for accurate, robust,
and efficient spectral fitting; AMARES) in the jMRUI software
package [24] as described previously [23]. In short, spectral
analysis of the 31P MR spectra was done by fitting the PCr peak to
Lorentzian and the inorganic phosphate (Pi) as well as the a-, b-
and c-ATP peaks to Gaussian line shapes. Intracellular pH was
calculated from the chemical shift difference between the Pi and
PCr resonances [25]. For the time series, the concentrations of
PCr determined during recovery were fit to a mono-exponential
function using Matlab (version 7.11.0, Mathworks, Natick, MA,
USA) yielding a rate constant, kPCr, which is a measure of skeletal
muscle mitochondrial oxidative capacity. For each rat, results from
two time series with end-stimulation pH values higher than 6.9
were averaged [26].
Determination of the relative mitochondrial DNA copy
number
The relative mitochondrial-DNA copy number was measured
as described previously [27]. Briefly, genomic DNA was isolated
from a 25 mg transversal slice of mid-belly TA using GenElute
Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich,
Zwijndrecht, The Netherlands). Mitochondrial DNA (mtDNA)
content relative to peroxisome proliferator-activated receptor-c
coactivator 1a (PGC-1a) gene was measured using real-time PCR
as described in [28].
High-resolution respirometry
Skeletal muscle mitochondria were isolated from whole TA
muscle through a differential centrifugation procedure as de-
scribed elsewhere [27]. Mitochondrial protein content was
determined using a BCA protein assay kit (Pierce, Thermo Fisher
Scientific Inc., Rockfort, IL, USA). Ex vivo mitochondrial function
was evaluated by measuring oxygen consumption rates (O2 flux) at
37uC using a 2-channel high-resolution Oroboros oxygraph-2k
(Oroboros, Innsbruck, Austria) as described previously [27]. O2
flux was fueled either with 5 mM pyruvate plus 5 mM malate
(Complex I respiration) or 5 mM succinate plus 1 mM rotenone
(Complex II respiration). Maximal rates of oxygen consumption
coupled to ATP synthesis, i.e. the OXPHOS state (classical state
3), was determined after addition of an ADP-regenerating system
consisting of excess hexokinase (4.8 U/ml), glucose (12.5 mM) and
ATP (1 mM). The resting state respiration, which compensates for
proton leak, i.e. the LEAK state (classical state 4), was assessed
after addition of 1.25 mM carboxyatractyloside (CAT). Finally, the
maximal capacity of the electron transfer system (ETS), i.e. the
ETS state (classical state U), was determined by uncoupling the
ETS from ATP synthesis with the addition of 1 mM carbonyl
cyanide 3-chlorophenyl hydrazone (CCCP) [29]. The respiratory
control ratio (RCR) was calculated as the ratio of OXPHOS to
LEAK states.
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High-resolution respirometry after in vitro incubation
with metformin
Isolated mitochondria from a cohort of water-treated lean and
diabetic ZDF rats (n = 5 per genotype) were incubated in assay
medium supplemented with metformin (1 mM) for 5 minutes in
the presence of pyruvate and malate or succinate plus rotenone (at
37uC), after which mitochondrial respiratory capacity was assessed
in the OXPHOS state. Results were expressed relative to the
oxygen consumption rates measured without incubation with
metformin.
For all HRR measurements, signals from the oxygen electrode
were recorded at 0.5-s intervals and measurements were done in
duplicate. Data acquisition and analysis was performed using
Oxygraph-2k-Datlab 4.3.1.15 software (Oroboros, Innsbruck,
Austria).
Statistical analysis
Data are presented as means 6 SD. Statistical significance of
genotype and treatment effects were assessed by applying a two-
way Analysis of Variance (ANOVA) in the IBM SPSS 20 statistical
package (SPSS Inc., Chicago, IL, USA). In case of a significant
effect of treatment, Bonferroni corrected post-hoc tests were
carried out in order to identify differences between different
treatment regimens. In case the interaction between genotype and
treatment was significant or borderline significant (P,0.1), the
differences were evaluated in more detail by separately analyzing
the effects of genotype and treatment using Bonferroni-corrected
two-sided unpaired t-tests. For determination of mitochondrial
respiratory capacity changes after in vitro incubation of mitochon-
dria with metformin, statistical analysis was done using a 262
mixed design ANOVA with one within-subjects factor (metformin
incubation) and one between-subjects factor (genotype) in SPSS.
The level of statistical significance was set at P,0.05.
Results
Animal characteristics
Animal characteristics after 2 weeks of treatment are summa-
rized in Table 1. Body weight was significantly higher in diabetic
animals compared with lean animals (P,0.01), except for the
water-treated groups (for which body weight also did not differ
before start of treatment). Fasting plasma glucose (P,0.001) and
insulin (P,0.01) were significantly higher in diabetic animals
compared with lean animals, independent of treatment regimen.
Two weeks of treatment with 30, 100 or 300 mg/kg/day
metformin had no effect on body weight, fasting plasma glucose,
or fasting plasma insulin in lean or diabetic animals.
In vivo muscle mitochondrial oxidative capacity
31P MRS was applied to assess the effect of metformin treatment
on in vivo mitochondrial oxidative capacity. Representative
examples of 31P MR spectra obtained from TA muscle at rest
and after 2 minutes of electrical stimulation are shown in Figure 1A
and 1B, respectively. PCr and Pi concentrations and intracellular
pH measured in TA muscle at rest and after muscle stimulation
are listed in Table 2. End-stimulation pH was significantly higher
in diabetic animals compared with lean animals (P,0.01),
independent of treatment regimen. However, the end-stimulation
pH was higher than 7.0 for all animals and therefore did not
influence PCr recovery kinetics. A mono-exponential function was
fitted through the PCr concentrations obtained during the
recovery phase (Figure 1C), yielding the PCr recovery rate
constant, kPCr, which is representative for muscle oxidative
capacity in vivo. kPCr was 25% lower in diabetic rats compared
with lean rats, independent of treatment regimen (P,0.001)
(Figure 1D). Two weeks of treatment with metformin had a
significant effect on in in vivo muscle oxidative capacity,
independent of genotype (P,0.001). Post-hoc testing revealed
that treatment of lean and diabetic rats with 30 mg/kg/day
metformin did not affect in vivo muscle oxidative capacity when
compared with water-treated controls. However, in rats treated
with metformin at a dosage of 100 and 300 mg/kg/day, in vivo
muscle oxidative capacity was 21% (P,0.001) and 47% (P,0.001)
lower, respectively, when compared with water-treated animals.
Mitochondrial content
Skeletal muscle oxidative capacity is determined by intrinsic
mitochondrial properties, as well as the number of mitochondria
in the tissue. Relative mtDNA copy number, which was used as an
estimate of mitochondrial content, did not differ between lean and
diabetic rats (Figure 2). Moreover, metformin treatment (300 mg/
kg/day) did not affect relative mtDNA copy number.
Ex vivo mitochondrial function
In order to evaluate ex vivo intrinsic mitochondrial function after
2 weeks of oral treatment with metformin, HRR was used to
measure O2 flux in mitochondria isolated from TA muscle, using
both Complex I- and Complex II-dependent substrates.
Complex I. Complex I-dependent respiratory capacity (driv-
en by pyruvate plus malate) in the OXPHOS state was not
different between lean and diabetic animals, except at the highest
metformin dosage (300 mg/kg/day), for which OXPHOS
respiratory capacity was lower in lean rats compared with diabetic
rats (P,0.05) (Figure 3). Whereas 2 weeks of treatment with
metformin at 30 mg/kg/day did not affect Complex I-dependent
respiratory capacity in the OXPHOS state, treatment at a dosage
of 100 and 300 mg/kg/day lowered OXPHOS respiratory
capacity compared with water treatment in both lean and diabetic
animals (P,0.05). In lean animals, Complex I-dependent
OXPHOS respiratory capacity was further reduced after metfor-
min treatment at 300 mg/kg/day compared with 100 mg/kg/day
(P,0.01), but this dose-dependent effect was not significant in
diabetic animals. In lean animals, Complex I-dependent respira-
tion in the LEAK state was lower after metformin treatment when
compared with water treatment, for all metformin dosages (P,
0.05) (Figure 3). As a consequence of the concomitant changes in
OXPHOS and LEAK states in response to metformin treatment,
the RCR’s, which give an indication of the coupling efficiency
between substrate oxidation and ATP synthesis, were not affected
in lean animals (Table 3). In diabetic rats, the LEAK state was
lower in the MET100 and MET300 groups compared with the
MET30 group only (P,0.001) and the RCR was higher in the
MET100 compared with MET30 group (P,0.05). In addition, the
RCR was higher in water-treated diabetic rats compared with
water-treated lean rats (P,0.05). In lean animals, treatment with
metformin at a dosage of 300 mg/kg/day lowered Complex I-
dependent respiratory capacity in the ETS state when compared
to all other treatment regimens (P,0.01) (Figure 3). In contrast,
metformin treatment had no significant effect on Complex I-
dependent ETS respiratory capacity in diabetic rats.
Complex II. Complex II-dependent respiratory capacity
(driven by succinate plus rotenone) in the OXPHOS state was
not different between lean and diabetic animals (Figure 4).
Moreover, treatment with metformin had no effect on Complex
II-dependent OXPHOS respiratory capacity, except for diabetic
rats treated with 300 mg/kg/day metformin, for which OXPHOS
respiratory capacity was lower than for diabetic rats treated with
100 mg/kg/day metformin (P,0.01). Complex II-dependent
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PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e100525
respiration in the LEAK state (Figure 4) and RCR’s (Table 3) were
not different between groups.
Mitochondrial function after in vitro incubation with
metformin
In order to assess whether metformin would affect mitochon-
drial respiratory capacity in vitro, mitochondria were isolated from
TA muscle excised from lean and diabetic rats, and incubated with
1 mM metformin for 5 min. Complex I- and Complex II-
dependent OXPHOS respiratory capacity were then determined
and normalized to OXPHOS respiratory capacity measured in the
isolated mitochondria without addition of metformin (Figure 5).
Complex I-dependent respiratory capacity in the OXPHOS state
decreased 28% after in vitro incubation with metformin, indepen-
dent of genotype (P,0.001). In contrast, incubation of isolated
mitochondria with metformin did not affect Complex II-depen-
dent respiratory capacity.
Discussion
A number of in vitro studies have shown that metformin inhibits
Complex I of the mitochondrial respiratory chain [3–9]. However,
the significance of this inhibition for in vivo skeletal muscle
mitochondrial function has yet to be elucidated. The aim of this
study was to clarify to which extent metformin affects in vivo and ex
vivo skeletal muscle oxidative capacity. To this end we assessed the
mitochondrial response to 2 weeks of treatment with metformin (0,
30, 100 or 300 mg/kg body weight/day) in a rat model of diabetes
using 31P MRS and HRR, respectively. We showed that 2 weeks
of treatment with metformin impairs in vivo muscle oxidative
capacity in a dose-dependent manner, both in healthy and in
diabetic rats. Whereas a dosage of 30 mg/kg/day had no
significant effect, in vivo oxidative capacity was 21% and 48%
lower after 2 weeks of metformin treatment at 100 and 300 mg/
kg/day, respectively, independent of genotype. HRR measure-
ments demonstrated a similar dose-dependent effect of metformin
on ex vivo respiratory capacity with a Complex I-dependent
substrate, whereas Complex II-dependent respiratory capacity was
largely unaffected.
In contrast to the current belief that metformin has only a mild
effect on mitochondrial function [30], we observed that metformin
may severely impair skeletal muscle oxidative capacity in vivo,
depending on the dosage. Two weeks of metformin treatment at
300 mg/kg/day led to a 2-fold reduction in the rate of PCr
recovery after muscle stimulation, both in lean and diabetic rats,
which is comparable to the 40% lower PCr recovery rate found in
sedentary individuals as compared with endurance athletes, who
run a minimum of 30 miles per week [31]. At 100 mg/kg/day,
metformin had a more moderate effect on in vivo muscle oxidative
capacity, while at 30 mg/kg/day no significant effect on PCr
recovery was observed. Patients with type 2 diabetes typically
receive an oral dose of metformin of approximately 30 mg/kg/
day. It should be noted though that the bioavailability of
metformin in the systemic circulation after oral treatment is lower
in rats (F = 30%, [22]) compared with patients (F = 56%, [32]).
Therefore treatment with ,100–300 mg/kg/day metformin in
rats is considered to be more clinically relevant, also because
therapeutic effects of metformin treatment in rats at that dosage
are similar to the effects in patients treated with 30 mg/kg/day
metformin [3,16–21]. It thus seems likely that patients with type 2
diabetes, possibly already featuring some level of mitochondrial
impairment, will be affected in daily life functioning or when
performing exercise as a consequence of treatment with metfor-
min. Interestingly, Braun et al. observed a small but significant
(2.7%) decrease in whole-body peak aerobic capacity (peak VO2)
in healthy volunteers after 9–12 days of treatment with 2000 mg/
day (which equals 30 mg/kg body weight/day) metformin [30].
Moreover, a study by Sharoff et al. demonstrated that exercise-
induced improvement of whole-body insulin sensitivity is lost in
insulin-resistant individuals taking metformin [15]. Their findings
essentially imply that metformin treatment in these patients limits
their ability to improve their peripheral insulin sensitivity through
exercise.
In vivo skeletal muscle oxidative capacity is determined by
intrinsic mitochondrial function as well as mitochondrial content.
However, we did not find a difference in relative mtDNA copy
number or PGC-1a protein expression (not shown) between rats
treated with metformin (300 mg/kg/day) and water-treated
controls, which implies that the observed reduction in in vivo
Table 1. Animal characteristics of lean and diabetic ZDF rats after 2 weeks of treatment with water or 30, 100 or 300 mg/kg body
weight/day metformin (MET30, MET100 and MET300, respectively).
Body weight (g) Fasting glucose (mM) Fasting insulin (pM)
Lean
Water 366611 4.060.6 297699
MET30 360618 4.961.2 205663
MET100 337631 4.160.3 213660
MET300 341623 4.461.1 184642
Diabetic
Water 380617 14.261.2 240650
MET30 406611## 13.265.5 3296128
MET100 386615### 14.761.7 4026166
MET300 409627### 15.160.8 4406164
Data is represented as mean 6 SD (n = 6 per group). Fasting plasma glucose (ANOVA: P,0.001) and insulin (ANOVA: P,0.01) were significantly higher in diabetic
animals compared with lean animals, independent of treatment regimen. For body weight, the interaction between genotype and treatment was significant and a
pairwise analysis of differences is provided by Bonferroni-corrected two-sided unpaired t-tests: ## P,0.01, ### P,0.001 when compared with lean animals of the same
treatment regimen.
doi:10.1371/journal.pone.0100525.t001
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skeletal muscle oxidative capacity after metformin treatment is not
caused by a decrease in mitochondrial content. In fact, Suwa et al.
[33] reported enhanced protein expression of PGC-1a and
increased citrate synthase activity in Wistar rats after 2 weeks of
treatment with metformin, suggesting a stimulation of mitochon-
drial biogenesis. However, the dosage regimen used in that study
was twice as high as the highest dosage used in the present study,
which might explain why we did not observe an effect on
mitochondrial biogenesis. Our results are in agreement with other
rodent studies showing that 2 or 4 weeks of metformin treatment
at ,300 mg/kg/day does not lead to increased activity of citrate
synthase [21,34].
In order to evaluate intrinsic mitochondrial function, we
performed HRR measurements in isolated muscle mitochondria
from rats treated with metformin using both Complex I- and
Complex II-dependent substrates. Two weeks of treatment with
metformin affected Complex I-dependent respiratory capacity in
the OXPHOS state, similar to the dose-dependent effect observed
for in vivo muscle oxidative capacity. At 300 mg/kg/day, Complex
I-dependent respiratory capacity in the OXPHOS state was
,40% lower than in water-treated controls, which is comparable
to the 48% reduction in in vivo muscle oxidative capacity. For lean
rats, the effect of metformin on Complex I-dependent respiratory
capacity in the OXPHOS state was similar to that in the ETS
Figure 1. In vivo oxidative capacity of tibialis anterior (TA) muscle, assessed by 31P MRS. Representative examples of 31P MR spectra
obtained during rest with 32 averages (A) and at the end of the electrical-stimulation protocol with 4 averages (B). (C) Representative examples of
relative PCr concentrations during rest, muscle stimulation and recovery (time resolution = 20 s) for a water-treated diabetic rat (open symbols) and
a diabetic rat treated with metformin at 300 mg/kg body weight/day (filled symbols). PCr concentrations are expressed as a percentage of the resting
PCr concentration. Mono-exponential functions (dark lines) were fit to the recovery data and the PCr recovery rate constants were 0.63 and 0.21 min-1
for the water-treated and metformin-treated animal, respectively. (D) Rate constants of PCr recovery, kPCr, after electrical stimulation in TA muscle of
lean and diabetic rats treated with water or 30, 100 or 300 mg/kg body weight/day metformin (MET30, MET100 and MET300 respectively). Data is
represented as mean 6 SD (n = 6 per group). kPCr was significantly lower in diabetic rats compared with lean rats, independent of treatment regimen
(ANOVA: P,0.001). In addition, treatment had a significant effect on kPCr, independent of genotype, and a pairwise analysis of differences is provided
by Bonferroni-corrected post-hoc tests: * P,0.001 when compared with water-treated animals, { P,0.001 when compared with MET30-treated
animals, ` P,0.001 when compared with MET100-treated animals.
doi:10.1371/journal.pone.0100525.g001
Metformin Impairs Muscle Mitochondrial Function







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Metformin Impairs Muscle Mitochondrial Function
PLOS ONE | www.plosone.org 6 June 2014 | Volume 9 | Issue 6 | e100525
state, indicating that the effect of metformin is confined to the
respiratory chain. Moreover, metformin did not increase respira-
tion in the LEAK state. Therefore, it seems that the effect of
metformin on in vivo muscle oxidative capacity can be fully
explained by its inhibition of Complex I-dependent respiration.
The inhibitory action of metformin on Complex I-dependent
respiration has been demonstrated before in in vitro studies, in
which isolated mitochondria from rat liver [3–5] and skeletal
muscle [4], as well as permeabilized cells [3,6,7] were incubated
with metformin. Reports on Complex I activity in cultured cells
further support an inhibitory effect of metformin on Complex I
[4,7]. In contrast, other ex vivo animal studies reported no effects on
the respiratory capacity of permeabilized muscle fibers obtained
from the oxidative part of the gastrocnemius of obese Zucker rats
after 4 weeks of treatment with metformin (320 mg/kg/day) [34]
and the predominantly glycolytic TA of wild type mice after 2
weeks of treatment with metformin (300 mg/kg/day) [21].
Likewise, it was shown that in permeabilized vastus lateralis muscle
fibers of type 2 diabetes patients treated with metformin
(20006200 mg/day) Complex I-dependent respiratory capacity
was not different compared with healthy control subjects,
indicating that mitochondrial Complex I respiration is not
inhibited by metformin [35]. Surprisingly, in L6 muscle cell
cultures [36] and in skeletal muscle of kinase dead AMPK mice
[21] metformin even increased mitochondrial energy formation.
The discrepancies across the literature could be caused by
differences in species, dosing regimens, muscle fiber types, and
the methods used to determine the effect of metformin on the
mitochondria. However, when comparing our results with the ex
vivo animal studies of Kane et al. [34] and Kristensen et al. [21], in
which metformin did not affect mitochondrial respiration in either
oxidative or glycolytic muscle from rats or mice after 2–4 weeks of
metformin treatment at ,300 mg/kg/day, it seems that all except
methodological differences can be excluded. In the current study
mitochondria were isolated from a whole TA muscle to allow
comparison with the in vivo data, while Kane et al. and Kristensen
et al. used permeabilized muscle fibers. It has recently been
reported that the respiratory response in permeabilized fibers can
be different from that of isolated mitochondria [37].
In this study, Complex II-dependent OXPHOS respiratory
capacity was largely unaffected by metformin treatment. This is in
agreement with previous reports showing that metformin has no
effect on Complex II-dependent respiratory capacity [4,6]. Scha¨fer
and Rieger postulated that metformin inhibits the activity of the
oxidative phosphorylation enzymes by binding to the mitochon-
drial membrane phospholipids and modifying physicochemical
membrane properties [10]. Following this reasoning, it is not
Figure 2. Relative mitochondrial-DNA copy number of lean and
diabetic rats after 2 weeks of treatment with either water or
metformin (300 mg/kg bodyweight/day). Data is represented as
mean 6 SD (n = 6 per group).
doi:10.1371/journal.pone.0100525.g002
Figure 3. O2 consumption rates determined in mitochondria isolated from TAmuscle of lean and diabetic rats treated with water or
30, 100 or 300 mg/kg body weight/day metformin (MET30, MET100 andMET300, respectively) for 2 weeks, fueled by pyruvate plus
malate (Complex I-dependent substrate). Respiratory capacity was determined in the OXPHOS state, when mitochondrial respiration is coupled
to ATP synthesis; the LEAK-state, when the system is limited by ADP; and the ETS state, after uncoupling of the ETS from ATP synthesis. Data is
represented as mean 6 SD (n = 6 per group). For the OXPHOS state, the interaction between genotype and treatment was borderline significant and
for the LEAK and ETS state, the interaction between genotype and treatment was significant. A pairwise analysis of differences is provided by
Bonferroni-corrected two-sided unpaired t-tests: * P,0.05 when compared with water-treated animals of the same genotype, { P,0.05 when
compared with MET30-treated animals of the same genotype, ` P,0.05 when compared with MET100-treated animals of the same genotype, # P,
0.05 when compared with lean animals of the same treatment regimen.
doi:10.1371/journal.pone.0100525.g003
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surprising that the activity of Complex I, the largest and most
complex enzyme among the enzymes involved in the oxidative
phosphorylation pathway, is impaired the most by metformin. Our
observation that Complex II-dependent OXPHOS capacity in
mitochondria from diabetic rats treated with 300 mg/kg/day
metformin was lower than for diabetic rats treated with 100 mg/
kg/day metformin suggests that the activity of Complex II or of
downstream electron transport chain complexes (i.e Complex III
and/or IV) is impaired by a high dosage of metformin. This
inhibitory effect could be partially caused by a progressively larger
derangement of the inner mitochondrial membrane by a high
concentration of metformin [10], impairing the activity of smaller
ETC complexes. Possibly, mitochondria from skeletal muscle of
diabetic animals are more sensitive to the toxic metformin effect
due to other factors related to the diseased environment, since we
do not observe inhibition of Complex II-dependent respiration in
mitochondria from lean animals. However, our results on
Complex I-dependent respiration do not support the notion that
mitochondria from diabetic muscle are more sensitive to
metformin-induced membrane derangements.
Although it is well established that metformin attenuates
Complex I-dependent respiratory capacity, the mechanism
through which metformin exerts its inhibitory action on Complex
I is still subject of debate. A number of reports propose an indirect
pathway, involving cell membrane events, via which metformin
affects mitochondrial respiration [6,8]. This is based on the
Table 3. Respiratory control ratios (RCR’s) in mitochondria isolated from TA muscle of lean and diabetic rats treated with water or
30, 100 or 300 mg/kg body weight/day metformin (MET30, MET100 and MET300, respectively) for 2 weeks, fueled by pyruvate plus














Data is represented as mean6 SD (n = 6 per group). For the RCR with pyruvate, the interaction between genotype and treatment was significant and a pairwise analysis
of differences is provided by Bonferroni-corrected two-sided unpaired t-tests: # P,0.05 when compared with lean animals of the same treatment regimen,{ P,0.05
when compared with MET30-treated animals of the same genotype.
doi:10.1371/journal.pone.0100525.t003
Figure 4. O2 consumption rates determined in mitochondria isolated from TAmuscle of lean and diabetic rats treated with water or
30, 100 or 300 mg/kg body weight/day metformin (MET30, MET100 and MET300 respectively) for 2 weeks, fueled by succinate plus
rotenone (Complex II-dependent substrate). Respiratory capacity was determined in the OXPHOS state, when mitochondrial respiration is
coupled to ATP synthesis; and the LEAK-state, when the system is limited by ADP. Data is represented as mean 6 SD (n = 6 per group). For the
OXPHOS state, the interaction between genotype and treatment was significant and a pairwise analysis of differences is provided by Bonferroni-
corrected two-sided unpaired t-tests: ` P,0.05 when compared with MET100-treated animals of the same genotype.
doi:10.1371/journal.pone.0100525.g004
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observation that inhibition of Complex I is lost when metformin is
added to mitochondria isolated from their cellular environment
[6] or when metformin is micro-injected into the interior of an
intact oocyte, suggesting membrane-mediated events are necessary
for this effect to occur [6,8]. Others, however, have shown that
metformin does inhibit Complex I in mitochondria isolated from
skeletal muscle and liver [3,4], thus contradicting the suggestion
that an intact cell is needed for metformin to exert its effect on
mitochondrial function. Early work of Scha¨fer and Rieger [10]
showed that biguanides have an affinity to directly bind to
mitochondrial membrane phospholipids, causing the accumula-
tion of positive charge at the membrane surface, thereby rendering
the electrostatic surface potential more positive. This will alter the
physicochemical properties of the mitochondrial membrane,
which may underlie the inhibition of metformin of Complex I
and which supports a direct pathway for metformin to affect
mitochondria. In order to determine whether metformin affects
mitochondrial respiratory capacity via a direct or indirect
pathway, we studied mitochondrial respiration after incubating
isolated mitochondria with 1 mM metformin for 5 min. We
observed a 28% inhibition of Complex I-dependent respiratory
capacity, whereas Complex II-dependent respiratory capacity was
unaffected. Our findings thus imply that metformin inhibits
mitochondrial respiration through Complex I via a direct
pathway.
Apart from the effects of metformin on muscle mitochondrial
function, we observed that in vivo muscle oxidative capacity was
25% lower in diabetic rats compared with lean control animals,
independent of treatment regimen. However, relative mtDNA
copy number and Complex I- and Complex II-dependent
respiratory capacity were similar between diabetic and lean
animals, which implies that neither a lower mitochondrial content
nor an impairment of their ex vivo intrinsic function can account for
the lower in vivo muscle oxidative capacity in diabetic rats. Instead,
it suggests that in diabetic muscle the functioning of mitochondria
in their natural cellular environment is impaired by factors that are
not taken into account during the ex vivo measurements in isolated
mitochondria, such as lipid-induced mitochondrial uncoupling
[27].
The beneficial effects of metformin on glucose homeostasis are
well established both in patient and animal studies [19,34,38–41].
However, in this study no changes in fasting plasma levels of
glucose or insulin were observed in any of the animal groups after
2 weeks of treatment with metformin. It should be noted, though,
that the therapy duration in our study was shorter than in the
animal studies in which improved glucose tolerance was observed
(typically 3 to 4 weeks) [34], which might explain why plasma
parameters were unaffected in our study.
There are indications that the inhibition of Complex I
contributes to metformin’s therapeutic efficacy. It is well-known
that metformin lowers blood glucose levels primarily by lowering
glucose production in the liver, which is an ATP-dependent
process. Therefore it is possible that the reduction of mitochon-
drial oxidative capacity underlies the mechanism through which
metformin suppresses glucose release from the liver [39].
Moreover, there are several reports indicating that metformin
promotes glucose uptake in peripheral tissues, thus contributing to
its antihyperglycemic efficacy. This could be conciliated with its
action on mitochondria by the ‘‘energy charge hypothesis’’
postulated by Brunmair et al. [4]. This hypothesis states that
agents that interfere with Complex I-dependent cellular respira-
tion affect enzymes like AMP-dependent protein kinase and hence
induce a metabolic response, such as increased glucose uptake and
glycolysis, to compensate for decreased ATP synthesis rates [3,4].
In conclusion, we demonstrated that 2 weeks of treatment with
metformin compromised in vivo and ex vivo muscle oxidative
capacity in ZDF rats in a dose-dependent manner. Moreover, our
finding that also in vitro incubation of isolated mitochondria with
metformin lowers Complex I-dependent respiratory capacity
supports the hypothesis that metformin inhibits Complex I via a
direct pathway.
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